Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)

Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and their long-term prognosis remains poor. Epidermal growth factor receptor (EGFR)-targeted therapies, such as gefitinib, have been subjected to comprehensive clinical development. Several phase II and III trials ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiseo, M, Bartolotti, M, Gelsomino, F, Bordi, P
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880339/
https://www.ncbi.nlm.nih.gov/pubmed/20531963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880339/
https://www.ncbi.nlm.nih.gov/pubmed/20531963

Ejemplares similares